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OBJECTIVES The aim of this study was to examine the association between atherosclerosis risk factors,
aortic atherosclerosis and aortic valve abnormalities in the general population.
BACKGROUND Clinical and experimental studies suggest that aortic valve sclerosis (AVS) is a manifestation
of the atherosclerotic process.
METHODS Three hundred eighty-one subjects, a sample of the Olmsted County (Minnesota) popula-
tion, were examined by transthoracic and transesophageal echocardiography. The presence of
AVS (thickened valve leaflets), elevated transaortic flow velocities and aortic regurgitation
(AR) was determined. The associations between atherosclerosis risk factors, aortic athero-
sclerosis (imaged by transesophageal echocardiography) and aortic valve abnormalities were
examined.
RESULTS Age, male gender, body mass index (odds ratio [OR]: 1.07 per kg/m2; 95% confidence
interval [CI]: 1.02 to 1.12), antihypertensive treatment (OR: 1.93; CI: 1.12 to 3.32) and
plasma homocysteine levels (OR: 1.89 per twofold increase; CI: 0.99 to 3.61) were
independently associated with an increased risk of AVS. Age, body mass index and pulse
pressure (OR: 1.21 per 10 mm Hg; CI: 1.00 to 1.46) were associated with elevated (upper
quintile) transaortic velocities, whereas only age was independently associated with AR.
Sinotubular junction sclerosis (p 5 0.001) and atherosclerosis of the ascending aorta (p 5
0.03) were independently associated with AVS and elevated transaortic velocities, respec-
tively.
CONCLUSIONS Atherosclerosis risk factors and proximal aortic atherosclerosis are independently associated
with aortic valve abnormalities in the general population. These observations suggest that
AVS is an atherosclerosis-like process involving the aortic valve. (J Am Coll Cardiol 2001;
38:827–34) © 2001 by the American College of Cardiology
Calcific (“degenerative”) aortic valve disease is the most
common etiology of acquired aortic valve stenosis (1).
Histopathologically, the early lesions of aortic valve sclerosis
(AVS) resemble arterial atherosclerotic plaques (2). Fur-
thermore, atherosclerosis risk factors (3,4) and clinical
atherosclerotic cardiovascular disease (5) are independently
associated with AVS, suggesting that AVS represents an
atherosclerosis-like process involving the aortic valve (6).
The objectives of our study were to examine the associ-
ations between atherosclerosis risk factors, anatomically
defined atherosclerosis (atherosclerosis of the thoracic aorta
imaged by transesophageal echocardiography [TEE]) and
aortic valve abnormalities in the general population. Aortic
valve morphology and function were assessed comprehen-
sively by a combination of transthoracic echocardiography
(TTE) and TEE in a population-based cohort.
METHODS
Study population. The study design and initial results of
the first phase of the SPARC (Stroke Prevention: Assess-
ment of Risk in a Community) study have been presented in
detail (7,8). In brief, the SPARC study was designed to
evaluate the prevalence of risk factors for stroke in the
general population. The original study cohort consisted of
581 subjects, an age- and gender-stratified random sample
of the Olmsted County (Minnesota) population ($45 years
old), who were evaluated by multiple modalities, including
echocardiography. Approximately four to five years after
their initial evaluation (median: 4.6 years; range: 3.8 to 5.4
years), eligible participants were enrolled in the second
phase of SPARC. Of 504 subjects eligible for the second
study phase (excluding 3 subjects lost to follow-up, 54
deceased subjects and 20 with severe medical disabilities
precluding participation), 392 (78%) agreed to participate
(age of participants and subjects refusing to participate were
From the *Division of Cardiovascular Diseases and Internal Medicine, †Depart-
ment of Neurology, and ‡Department of Health Science Research, Mayo Clinic and
Mayo Foundation, Rochester, Minnesota. Dr. Agmon is now at the Rambam
Medical Center in Haifa, Israel. Supported, in part, by research grant NS06663 from
the NINDS. Presented, in part, at the 73rd Scientific Sessions of the American Heart
Association, November 2000, New Orleans, Louisana (abstract published in Circu-
lation 1999;102 Suppl:II760).
Manuscript received September 26, 2000; revised manuscript received May 1, 2001,
accepted May 17, 2001.
Journal of the American College of Cardiology Vol. 38, No. 3, 2001
© 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00
Published by Elsevier Science Inc. PII S0735-1097(01)01422-X
not significantly different). Echocardiography was success-
fully repeated in 388 of the participants (99%). Seven
subjects were excluded from the current analysis (three with
aortic prostheses, three with bicuspid aortic valves and one
patient with incomplete echocardiographic data). None
were excluded because of rheumatic valve disease (none had
mitral stenosis or have had mitral valve surgery for rheu-
matic valve disease). The final study group consisted of 381
subjects (median age: 67 years; range: 51 to 101; 52% men).
The study was approved by the Institutional Review Board.
Written, informed consent was obtained from all partici-
pants.
Clinical and laboratory data. Cardiovascular risk factors
and clinical manifestations of coronary artery and cerebro-
vascular disease were assessed by an interview and by
medical records abstracting (at Mayo Clinic and Olmsted
Medical Center, the two primary health care providers in
Olmsted County, Minnesota). Blood pressure measure-
ments were taken during an office appointment related to
SPARC. Two blood pressure measurements were taken in
the sitting position, 5 to 10 min apart, and averaged. Pulse
pressure was defined as the difference between mean systolic
and mean diastolic measurements. Treatment of hyperten-
sion or hyperlipidemia was defined as current use of anti-
hypertensive or lipid-lowering medications, respectively
(self-reported during interview).
Fasting blood samples were collected on the day of the
echocardiographic examination. Plasma lipids (total choles-
terol, high-density lipoprotein [HDL] cholesterol, triglyc-
erides), apolipoprotein A-I, apolipoprotein B and homocys-
teine levels were determined using standard commercially
available assays, and low-density lipoprotein (LDL) choles-
terol levels were calculated.
Echocardiographic evaluation. Transthoracic echocardi-
ography and multiplane TEE (9) were performed applying
standard practice guidelines and using commercially avail-
able ultrasound instruments. Local pharyngeal anesthesia
and intravenous sedation (midazolam and meperidine) were
used during TEE, as clinically indicated. All TEE exami-
nations were performed using an Acuson Sequoia ultra-
sound machine (Acuson, Mountain View, California).
Aortic valve. The morphology of the aortic valve was
assessed during TEE by high-frequency (7 MHz), high-
resolution imaging of the valve in multiple (short- and
long-axis) echocardiographic views (9,10). “Aortic valve
sclerosis” was defined as abnormal irregular thickening of
the aortic valve leaflets (at least one abnormal leaflet per
valve) (Fig. 1). A stratified random sample of 46 TEE
studies was blindly reviewed off-line by the initial operator
performing the echocardiographic studies and by a second
reviewer. Given the good intraobserver agreement (compar-
ison of initial and off-line interpretation: kappa 5 0.63; 95%
confidence interval [CI]: 0.40 to 0.85) and interobserver
agreement (comparison of off-line interpretation by both
reviewers: kappa 5 0.63; CI: 0.43 to 0.84), the initial
echocardiographic interpretation was taken for all subse-
quent analyses, as previously reported (4).
Peak transaortic flow velocities were measured during the
TTE examination by continuous-wave Doppler (11) (aver-
age of triplicate measurements). The presence of aortic valve
regurgitation (AR) was determined by color flow imaging in
multiple planes during the TEE examination. Higher
transaortic flow velocities (12) and AR (13) were examined
as functional surrogates of AVS.
Aortic atherosclerosis. The ascending aorta, aortic arch
and descending thoracic aorta were imaged by TEE in
multiplane short- and long-axis views. “Atherosclerosis” was
defined as irregular intimal thickening ($2 mm) with
increased echogenicity. “Sinotubular junction sclerosis” was
defined as focal, highly-echogenic thickening ($2 mm) of
the sinotubular junction (14). The presence of aortic ath-
erosclerosis (any degree of atherosclerosis in any segment of
Abbreviations and Acronyms
AR 5 aortic regurgitation
AVS 5 aortic valve sclerosis
CAD 5 coronary artery disease
CI 5 95% confidence interval(s)
HDL 5 high-density lipoprotein
LDL 5 low-density lipoprotein
OR 5 odds ratio(s)
SPARC 5 Stroke Prevention: Assessment of Risk in a
Community study
TEE 5 transesophageal echocardiography
TTE 5 transthoracic echocardiography
Figure 1. Transesophageal echocardiographic examples of normal (A) and
sclerotic (B) aortic valves. Note the irregular thickening of the sclerotic
aortic valve leaflets. Ao 5 aorta; LVOT 5 left ventricular outflow tract.
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the thoracic aorta), proximal atherosclerosis (sinotubular
junction sclerosis and atherosclerosis of the ascending aorta)
and severe atherosclerosis (maximal plaque thickness
$4 mm [15], plaque thickness $6 mm and mobile debris in
any segment of the thoracic aorta) was determined.
Statistical analysis. Continuous data are summarized as
medians and interquartile ranges (25% to 75%) and cate-
gorical data as percentages. Group comparisons involving
continuous data were performed using Student t test or the
Wilcoxon rank-sum test and comparisons involving cate-
gorical data using chi-square statistics or Fisher exact test, as
appropriate.
The associations between atherosclerosis risk factors (Ta-
ble 1) and aortic valve abnormalities (AVS, elevated
transaortic velocities [in the upper quintile of the study
group] and AR) were examined by univariate and multivar-
iate logistic regression. Initially, the age- and gender-
adjusted associations were examined. Subsequently, multi-
variate risk factor models were developed by stepwise
(forward and backward) logistic regression, allowing all
atherosclerosis risk factors to compete for their entry into
the models. Age and gender were forced into all models.
The p value to enter and to leave the models was 0.05. All
two-way interactions between the final variables in the
models were examined.
The associations between aortic atherosclerosis variables
and aortic valve abnormalities were examined by logistic
regression, adjusting for age and gender and subsequently
adjusting for age, gender and all additional variables in
the multivariate risk factor models. The associations be-
Table 1. Clinical and Laboratory Characteristics of Subjects With Aortic Valve Sclerosis, Upper Quintile Transaortic Flow Velocities
and Aortic Regurgitation
Aortic Sclerosis Transaortic Flow Velocities Aortic Regurgitation
Present
(n 5 140; 36.7%)
Absent
(n 5 241; 63.3%)
Upper Quintile
(n 5 68)
Lower Quintiles
(n 5 302)
Present
(n 5 113; 29.8%)
Absent
(n 5 266; 70.2%)
Age, yr 76 (67–85)‡ 63 (57–69) 71 (63–84)‡ 65 (59–74) 73 (64–84)‡ 64 (58–71)
Men, % 61* 47 46 53 57 51
Height, cm 167 (160–174) 167 (160–175) 164 (156–172)* 167 (160–174) 167 (158–175) 167 (161–174)
Weight, kg 81 (71–92) 80 (67–94) 79 (68–97) 81 (69–92) 79 (66–90) 81 (70–94)
BMI, kg/m2 28 (26–33) 28 (25–32) 28 (26–35) 28 (25–32) 27 (24–32)* 29 (26–33)
BSA, m2 1.9 (1.8–2.0) 1.9 (1.7–2.1) 1.9 (1.7–2.0) 1.9 (1.7–2.1) 1.9 (1.7–2.0) 1.9 (1.8–2.1)
Heart rate, beats/min 61 (54–70) 61 (54–69) 61 (52–71) 61 (54–69) 60 (52–69) 61 (54–69)
Systolic BP, mm Hg 139 (126–149)‡ 128 (118–140) 142 (126–153)‡ 131 (119–143) 136 (122–149)* 130 (119–143)
Diastolic BP, mm Hg 82 (75–87) 82 (76–88) 82 (75–87) 82 (75–88) 81 (73–87) 82 (76–88)
Pulse pressure, mm Hg 54 (46–71)‡ 46 (38–56) 54 (46–74)‡ 49 (40–59) 52 (47–67)‡ 47 (39–58)
Antihypertensive drugs, % 53‡ 25 51† 31 38 34
Diabetes mellitus, % 14 8 16 9 15* 8
Insulin treatment, % 2 2 4 2 2 3
Ever smoking, % 47 44 50 44 41 47
Current smoking, % 4 9 6 7 4 9
Total cholesterol, mg/dl 198 (175–218) 206 (182–226) 201 (174–225) 204 (180–223) 197 (178–216) 205 (181–226)
HDL cholesterol, mg/dl 51 (41–62) 53 (44–66) 54 (42–70) 53 (42–64) 54 (43–67) 51 (42–64)
Total cholesterol/
HDL cholesterol ratio
4.0 (3.2–4.9) 3.9 (3.0–4.7) 3.6 (2.9–4.6) 4.0 (3.1–4.8) 3.7 (2.9–4.6) 4.0 (3.1–4.9)
LDL cholesterol, mg/dl 110 (90–132) 118 (96–136) 110 (85–127) 117 (94–136) 112 (90–129) 118 (95–136)
Triglycerides, mg/dl 151 (116–206) 149 (113–193) 141 (103–196) 150 (117–195) 139 (110–178) 154 (115–203)
Apo A-I, mg/dl 145 (125–166)† 153 (133–175) 151 (129–171) 149 (131–171) 153 (130–171) 148 (130–171)
Apo B, mg/dl 103 (89–114) 102 (88–115) 99 (84–115) 103 (89–115) 100 (85–113) 103 (90–116)
Lipid lowering drugs, % 23 20 21 21 20 21
Homocysteine, mmol/l 11.1 (9.1–13.5)‡ 8.9 (7.4–11.1) 10.7 (7.9–12.9) 9.6 (7.8–11.6) 10.4 (8.4–12.1)* 9.4 (7.6–11.8)
Coronary artery disease§, % 29‡ 10 18 17 23* 15
Previous MI, % 16† 5 10 9 12 8
Angina pectoris, % 24‡ 9 13 15 19 12
PTCA, % 6 2 3 4 5 3
CABG, % 10† 3 9 4 7 5
Cerebrovascular disease\, % 14* 6 18† 7 11 8
Stroke, % 5 3 10† 3 4 4
TIA, % 8 4 9 5 7 5
Carotid endarterectomy, % 3* 0 3 1 2 1
Continuous data presented as medians (interquartile ranges in parentheses); categorical data presented as percentages. *p # 0.05; †p , 0.01; ‡p , 0.001 for comparisons of
subjects with aortic sclerosis, upper quintile transaortic velocities and aortic regurgitation to subjects without these abnormalities; §coronary artery disease defined as previous
myocardial infarction, angina pectoris, PTCA or CABG; \cerebrovascular disease defined as previous stroke, TIA or carotid endarterectomy.
Apo 5 apolipoprotein; BMI 5 body mass index; BP 5 blood pressure; BSA 5 body surface area; CABG 5 coronary artery bypass grafting; HDL 5 high-density lipoprotein;
LDL 5 low-density lipoprotein; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty; TIA 5 transient ischemic attack.
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tween clinical coronary artery disease (CAD), cerebrovas-
cular disease and aortic valve abnormalities were assessed
similarly.
RESULTS
Atherosclerosis risk factors and aortic valve abnormali-
ties. AVS. The aortic valves were sclerotic in 140 subjects
(36.7%). The clinical and laboratory characteristics of sub-
jects with and without AVS are presented in Table 1.
Subjects with AVS were significantly older than subjects
without AVS (median age, 76 vs. 63 years, respectively; p ,
0.001) and were more commonly men (61 vs. 47%, respec-
tively; p 5 0.01). Weight, body mass index, body surface
area, antihypertensive drug treatment and plasma homocys-
teine levels were associated with AVS, adjusting for age and
gender, whereas blood pressure measurements (systolic,
diastolic or pulse pressure), diabetes mellitus, smoking and
blood lipid levels were not. By multivariate analysis, age,
male gender, body mass index, antihypertensive treatment
and homocysteine levels were independently associated with
AVS. A statistically significant interaction (p , 0.001), best
described graphically (Fig. 2), was apparent between age
and gender regarding their association with AVS. There
was approximately a decade difference between men and
women in the age-associated increase in frequency of AVS
(earlier increase in men). The odds of AVS were higher with
higher body mass index (odds ratio [OR]: 1.07 for every 1
kg/m2 increase in body mass index; CI: 1.02 to 1.12; p 5
0.006), were greater in subjects treated for hypertension
(OR: 1.93; CI: 1.12 to 3.32; p 5 0.02) and were higher with
higher homocysteine levels (OR: 1.89 per twofold increase
in homocysteine levels; CI: 0.99 to 3.61; p 5 0.05).
TRANSAORTIC FLOW VELOCITIES. The median value of
transaortic flow velocities (data available in 370 study
participants) was 1.3 m/s. Transaortic velocities were di-
chotomized at approximately the 80th percentile of the
study group (1.50 m/s). Velocities were in the upper quintile
($1.50 m/s) in 30% of subjects with AVS compared with
12% of subjects without AVS (p , 0.001), supporting the
use of transaortic velocities as hemodynamic surrogates of
AVS. Velocities .2.5 m/s, indicating aortic stenosis (4),
were present in only five subjects, all with AVS.
The clinical and laboratory characteristics of subjects
with and without elevated (upper quintile) transaortic ve-
locities are presented in Table 1. Subjects with upper
quintile velocities ($1.50 m/s) were significantly older
than subjects with lower (,1.50 m/s) velocities (median
age: 71 years vs. 65 years, respectively; p , 0.001) (Fig. 3).
Weight, body mass index, pulse pressure and antihyperten-
sive treatment were associated with upper quintile velocities,
adjusting for age and gender, whereas heart rate and
other atherosclerosis risk factors including diabetes mel-
litus, smoking and lipid levels were not. By multivariate
analysis, age, body mass index and pulse pressure were
independently associated with upper quintile transaortic
velocities. A significant interaction was apparent between
age and body mass index regarding their association with
higher transaortic velocities (p 5 0.01). Age was associated
with upper quintile velocities in subjects with low and
intermediate body mass index; no pattern could be identi-
fied for the elderly with high body mass index because the
study sample did not contain such subjects. The odds of
upper quintile velocities increased with increasing pulse
pressure (OR: 1.21 for every 10 mm Hg increase; CI: 1.00
to 1.46; p 5 0.05).
Figure 2. Probability of aortic valve sclerosis by age and gender. Note the nonlinear relationship with age and the interaction between age and gender. There
is approximately a decade difference between men and women in the age-associated increasing frequency of aortic valve sclerosis (earlier in men). The marks
at the top and the bottom of the figure indicate individuals with and without aortic sclerosis, respectively.
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AR. Aortic regurgitation was detected in 113 subjects (30%
of 379 subjects with available data). Aortic regurgitation was
trivial-to-mild in 91 subjects (24%), moderate in 21 subjects
(6%) and severe in 1 subject (0.3%). The proportion of
subjects with AR was significantly higher among subjects
with AVS (56%) than it was among subjects with morpho-
logically normal aortic valves (15%) (p , 0.001), supporting
the use of AR as a surrogate of AVS. The clinical and
laboratory characteristics of subjects with and without AR
are presented in Table 1. Subjects with AR were signifi-
cantly older than subjects without AR (median age, 73 years
vs. 64 years, respectively; p , 0.001). None of the other risk
factors were significantly associated with AR after adjusting
for age and gender.
Association of aortic atherosclerosis and aortic valve
abnormalities. The proportion of subjects with aortic ath-
erosclerosis was higher in subjects with aortic valve abnor-
malities (Table 2). Sinotubular junction sclerosis and thick
($4 mm) atherosclerotic plaques were associated with AVS,
and atherosclerotic plaques in the ascending aorta were
associated with upper quintile transaortic velocities, adjust-
ing for age and gender (Table 3). Sinotubular junction
sclerosis and atherosclerosis in the ascending aorta were
associated with AVS and upper quintile velocities, respec-
tively, adjusting for age, gender and all additional variables
in the final risk factor models (Table 3).
Clinical CAD, cerebrovascular disease and aortic valve
abnormalities. The proportion of subjects with clinical
coronary artery and cerebrovascular disease was higher in
subjects with aortic valve abnormalities (Table 1). Angina
pectoris and previous coronary artery bypass surgery were
associated with AVS, and previous stroke was associated
with upper quintile transaortic velocities, adjusting for age
and gender (Table 4). These associations were no longer
significant after adjusting for all the variables in the final risk
factor models.
DISCUSSION
Our population-based study demonstrates that multiple
atherosclerosis risk factors (age, male gender, high blood
pressure, obesity and homocysteine levels) are associated
with AVS. Furthermore, anatomically defined atherosclero-
sis (echocardiographically delineated aortic atherosclerosis)
is independently associated with AVS. These observations
support the hypothesis that calcific (“degenerative”) aortic
Table 2. Aortic Atherosclerosis in Subjects With Aortic Valve Sclerosis and Upper Quintile
Transaortic Velocities
Aortic Sclerosis Transaortic Velocities
Present Absent Upper Quintile Lower Quintiles
Any aortic plaque 86‡ 60 75 68
Sinotubular junction sclerosis 34‡ 8 32‡ 15
Plaque-ascending aorta 12‡ 2 15† 4
Aortic plaque $4 mm 54‡ 16 43* 27
Aortic plaque $6 mm 20‡ 5 16 9
Mobile aortic debris 9* 3 6 5
Data presented as percentages. *p # 0.05; †p , 0.01; ‡p , 0.001.
Figure 3. Probability of upper quintile transaortic velocities by age and gender. The marks at the top and the bottom of the figure indicate individuals
with and without upper quintile velocities, respectively.
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valve disease represents an atherosclerosis-like process in-
volving the aortic valve (6).
Several unique features of our study design should be
noted. First, we used TEE to assess aortic valve morphology
in a population-based setting, an approach that consistently
allows high-resolution imaging of the valves. Second, given
the inherent limitations and subjectivity of qualitative eval-
uation of valve morphology (4), we examined the aortic
valves both morphologically and functionally. Previous
echocardiographic studies were based on transthoracic im-
aging (3,4) and, primarily, morphologic valve assessment
(4). Importantly, to our knowledge, our study is the first to
demonstrate an independent association between anatomi-
cally defined atherosclerosis and the morphophysiologic
features of degenerative aortic valve disease in a population-
based setting.
Risk factors for AVS. Multiple pathologic (16,17) and
echocardiographic studies (3,4,12,13,18) have demonstrated
a strong association between age and AVS, suggesting that
AVS represents a nonspecific wear-and-tear (“degenera-
tive”) phenomenon. Nevertheless, the risk of AVS is only
partially explainable by age, and several additional risk
factors may contribute to its development and progression
(6). Male gender has been associated with AVS (4,19),
although not uniformly (17,18). An earlier age-associated
increase in frequency of AVS in men was apparent in our
study, a finding reminiscent of the relationship between age,
gender and CAD.
An association between hypertension and AVS has been
reported almost uniformly in multiple studies (3,4,18,20), as
well as in our study, an association possibly resulting from
chronic hypertension-related mechanical stress upon the
aortic valve. Interestingly, our observation of the association
between pulse pressure and elevated transaortic velocities, a
surrogate for AVS, is similar to our recent description of the
association between pulse pressure and aortic atherosclerosis
(8), further emphasizing the similarity of these processes.
Diabetes (18,20) and smoking (4,19) have been associated
with AVS, although inconsistently (3). These associations
were not observed in our study.
Familial hypercholesterolemia is associated with early-
onset calcific aortic valve disease (21,22), suggesting a role
for dyslipidemia in the pathogenesis of AVS. The his-
topathologic findings in early aortic valve lesions support
this hypothesis (2), although the results of clinical studies
have been less uniform. Increased total cholesterol (18,20),
LDL cholesterol (4), lipoprotein(a) (4,23) and low HDL
-cholesterol (20) have been associated with AVS. In the
Table 4. Odds Ratios of Aortic Valve Sclerosis and Upper Quintile Transaortic Velocities in
Relation to Clinical Coronary Artery and Cerebrovascular Disease
Aortic Sclerosis
Upper Quintile Transaortic
Flow Velocities
Age- and
Gender-Adjusted
Final
Model-Adjusted
Age- and
Gender-Adjusted
Final
Model-Adjusted
Coronary artery disease 1.94 (1.01–3.76)* 1.69 (0.85–3.34) 0.78 (0.37–1.64) 0.66 (0.31–1.44)
Previous MI 1.27 (0.54–2.99) 0.92 (0.37–2.27) 0.83 (0.33–2.11) 0.70 (0.26–1.88)
Angina pectoris 2.17 (1.08–4.36)* 1.99 (0.97–4.09) 0.72 (0.32–1.61) 0.66 (0.29–1.53)
PTCA 2.26 (0.60–8.56) 2.06 (0.51–8.35) 0.77 (0.16–3.64) 0.71 (0.15–3.49)
CABG 3.02 (1.03–8.87)* 2.71 (0.89–8.21) 2.04 (0.72–5.82) 2.28 (0.76–6.85)
Cerebrovascular disease 0.79 (0.34–1.87) 0.63 (0.25–1.63) 1.92 (0.86–4.29) 2.00 (0.87–4.58)
Stroke 0.49 (0.14–1.72) 0.34 (0.09–1.33) 3.09 (1.03–9.26)* 2.80 (0.89–8.79)
TIA 0.63 (0.22–1.77) 0.49 (0.16–1.51) 1.24 (0.45–3.45) 1.40 (0.49–3.96)
Carotid endarterectomy, % Not estimable† Not estimable† 5.57 (0.75–41.4) 6.31 (0.81–48.9)
*p , 0.05; †all subjects with carotid endarterectomy had aortic valve sclerosis. Odds ratios adjusted for age and gender and
adjusted for age, gender and additional significant variables in the final multivariate models.
CABG 5 coronary artery bypass grafting; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty; TIA 5 transient ischemic attack.
Table 3. Odds Ratios of Aortic Valve Sclerosis and Upper Quintile Transaortic Flow Velocities
in Relation to Presence, Location and Severity of Aortic Atherosclerosis
Aortic Sclerosis
Upper Quintile Transaortic
Flow Velocities
Age- and
Gender-Adjusted
Final
Model-Adjusted
Age- and
Gender-Adjusted
Final
Model-Adjusted
Any aortic plaque 1.61 (0.82–3.13) 1.46 (0.74–2.89) 0.74 (0.36–1.52) 0.68 (0.32–1.43)
Sinotubular junction sclerosis 2.73 (1.40–5.31)† 3.24 (1.60–6.53)† 1.87 (0.96–3.65) 1.80 (0.89–3.62)
Plaque-ascending aorta 2.78 (0.93–8.36) 2.90 (0.92–9.13) 2.90 (1.14–7.36)* 2.97 (1.12–7.90)*
Aortic plaque $4 mm 2.31 (1.28–4.17)† 1.70 (0.91–3.19) 1.33 (0.67–2.61) 0.99 (0.48–2.02)
Aortic plaque $6 mm 1.65 (0.71–3.84) 1.28 (0.53–3.09) 1.19 (0.52–2.70) 1.03 (0.44–2.40)
Mobile aortic debris 1.67 (0.57–4.88) 1.27 (0.39–4.10) 0.79 (0.25–2.51) 0.71 (0.21–2.43)
Odds ratios adjusted for age and gender and adjusted for age, gender and additional significant variables in the final multivariate
models. Data presented as odds ratios (95% confidence intervals in parentheses). *p # 0.05; †p , 0.01.
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Cardiovascular Health Study, increased LDL cholesterol
and lipoprotein(a) were associated with AVS, although the
association of LDL cholesterol was weak (4). As in the
Helsinki Ageing Study (3), we did not detect any associa-
tion between dyslipidemia and aortic valve abnormalities,
suggesting a relatively lesser role for dyslipidemia in the
pathogenesis of aortic valve disease compared with the other
identified risk factors.
A strong association between increased body mass index
and aortic valve abnormalities, assessed morphologically and
functionally, was demonstrated in our study, whereas a lack
of association (4) or even a negative association (3) has been
previously reported. The discrepancy between these obser-
vations may be due to the limitation of TTE imaging in
obese subjects (3), which was overcome in our study by
using TEE. The relationship between obesity and aortic
valve abnormalities may be due to obesity-associated meta-
bolic abnormalities or increased mechanical stress upon the
aortic valve due to obesity-related hemodynamic changes.
We observed an association between increasing homo-
cysteine levels and AVS. This observation, which also
supports the analogy between AVS and the atherosclerotic
process, needs to be confirmed in additional studies.
Atherosclerosis and AVS. Aortic valve sclerosis is associ-
ated with clinical atherosclerotic cardiovascular disease (5),
as also observed in our study. To date, the association of
AVS with aortic atherosclerosis has only been described in
selected patients (24,25). To our knowledge, our study is the
first to demonstrate an independent association between
aortic atherosclerosis and aortic valve abnormalities in the
general population, suggesting that these disorders represent
related processes in the spectrum of atherosclerotic cardio-
vascular disease.
Aortic atherosclerosis was associated with aortic valve
abnormalities, adjusting for age and gender, supporting the
hypothesis that both pathologies share common risk factors.
Furthermore, aortic atherosclerosis was independently asso-
ciated with aortic valve abnormalities, after adjusting for
age, gender and other atherosclerosis risk factors, suggesting
that additional “nontraditional” risk factors may predispose
to both processes. Interestingly, atherosclerosis in proximity
to the aortic valve (sinotubular sclerosis and atherosclerosis
of the ascending aorta) was strongly associated with aortic
valve abnormalities. This finding is supported by observa-
tions in patients with familial hypercholesterolemia, in
whom aortic stenosis and supravalvular aortic atherosclerosis
frequently coincide (21,22).
Study limitations. The SPARC study is the largest
population-based TEE study published to date. The size of
our study population, which is smaller than that of the
Cardiovascular Health Study (4) but similar in size to the
Helsinki Ageing Study (3,12), may have limited our ability
to detect additional, albeit relatively less important, risk
factors for AVS. Specifically, the relatively minor role of
increased LDL cholesterol in the pathogenesis of AVS that
was observed in the Cardiovascular Health Study (4) but not
in SPARC or the Helsinki Ageing Study (3) may have
resulted from the smaller sample size of the latter two
studies.
The reported frequency of AVS varies widely between
studies (4,12,13,20,23), emphasizing the qualitative and
subjective nature of this echocardiographic diagnosis. The
frequency noted in our study (36.7%) is consistent with
previous observations in populations of similar age. In
addition to morphologic assessment, we examined the
association between atherosclerosis risk factors, aortic ath-
erosclerosis and subtle abnormalities of valve function (ele-
vated transaortic flow velocities and AR, which were minor
and clinically nonsignificant in the majority of subjects).
Although flow velocities were higher and AR was more
frequent in subjects with AVS, these functional variables
may have been affected by other factors in addition to aortic
valve structure. Nevertheless, the concordant results ob-
tained by morphologic valve assessment and transaortic
velocity measurements support our combined morphologic-
functional analysis. Despite the strong association between
AVS and AR (13), we were unable to detect any association
of atherosclerosis risk factors and AR after adjusting for age,
a finding concordant with previous data (26).
Conclusions. Multiple atherosclerosis risk factors and aor-
tic atherosclerosis are independently associated with AVS in
the general population. These observations support the
hypothesis that AVS is an atherosclerosis-like process in-
volving the aortic valve.
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